The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study
Open accessAbstract
OBJECTIVES: There is a need for effective and safe treatment during pregnancy in women with chronic inflammatory diseases. This study evaluated placental transfer of certolizumab pegol (CZP), an Fc-free anti-tumour necrosis factor drug, from CZP-treated pregnant women to their infants. METHODS: CRIB was a pharmacokinetic (PK) study of women ≥30 weeks pregnant receiving commercial CZP for a locally approved indication (last dose ≤35 days prior to delivery). Blood samples were collected from mothers, umbilical cords and infants at delivery, and infants again at weeks 4 and 8 post-delivery. CZP plasma concentrations were measured with a highly sensitive and CZP-specific electrochemiluminescence immunoassay (lower limit of quantification 0.032 μg/mL). RESULTS: Sixteen women entered and completed the study. Maternal CZP plasma levels at delivery were within the expected therapeutic range (median [range] 24.4 [5.0-49.4] μg/mL). Of the 16 infants, 2 were excluded from the per-protocol set: 1 due to missing data at birth and 1 due to implausible PK data. Of the remaining 14 infants, 13 had no quantifiable CZP levels at birth (<0.032 μg/mL), and 1 had a minimal CZP level of 0.042 μg/mL (infant/mother plasma ratio 0.0009); no infants had quantifiable CZP levels at weeks 4 and 8. Of 16 umbilical cord samples, 1 was excluded due to missing data; 3/15 had quantifiable CZP levels (maximum 0.048 μg/mL). CONCLUSIONS: foetal exposure during the third trimester. These results support continuation of CZP treatment during pregnancy, when considered necessary. TRIAL REGISTRATION NUMBER: NCT02019602; Results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1976.tb115280.x · Cited by 5,237
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Pasparakis, M., Alexopoulou, L., Episkopou, V, & Kollias, G. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.4.1397 · Cited by 1,160
Götestam Skorpen, C., Hoeltzenbein, M., Tincani, A., Fischer-Betz, R., Elefant, E., Chambers, C., da Silva, J., Nelson-Piercy, C., Cetin, I., Costedoat-Chalumeau, N., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208840 · Cited by 1,068
Self-citationde Man, Y. A., Dolhain, R. J. E. M., van de Geijn, F. E., Willemsen, S. P., & Hazes, J. M. W. (2008) · Arthritis Care & Research · doi:10.1002/art.24003 · Cited by 531
Mahadevan, U., Wolf, D. C., Dubinsky, M., Cortot, A., Lee, S. D., Siegel, C. A., Ullman, T., Glover, S., Valentine, J. F., Rubin, D. T., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.11.011 · Cited by 498
Flint, J., Panchal, S., Hurrell, A., van de Venne, M., Gayed, M., Schreiber, K., Arthanari, S., Cunningham, J., Flanders, L., Moore, L., et al. (2016) · Rheumatology · doi:10.1093/rheumatology/kev404 · Cited by 451
Mahadevan, U., Sandborn, W. J., Li, D., Hakimian, S., Kane, S., & Corley, D. A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.07.019 · Cited by 373
de Man, Y. A., Hazes, J. M. W., van der Heide, H., Willemsen, S. P., de Groot, C. J. M., Steegers, E. A. P., & Dolhain, R. J. E. M. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24914 · Cited by 361
Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection
Julsgaard, M., Christensen, L. A., Gibson, P. R., Gearry, R. B., Fallingborg, J., Hvas, C. L., Bibby, B. M., Uldbjerg, N., Connell, W. R., Rosella, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.04.002 · Cited by 328
Cited by
Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. N. W. N. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32549-6 · Cited by 2,383
Management of Rheumatoid Arthritis: An Overview
Radu, A.-F., & Bungau, S. G. (2021) · Cells · doi:10.3390/cells10112857 · Cited by 1,089
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Lin, Y.-J., Anzaghe, M., & Schülke, S. (2020) · Cells · doi:10.3390/cells9040880 · Cited by 932
Furer, V., Rondaan, C., Heijstek, M. W., Agmon-Levin, N., van Assen, S., Bijl, M., Breedveld, F. C., D'Amelio, R., Dougados, M., Kapetanovic, M. C., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215882 · Cited by 829
Sammaritano, L. R., Bermas, B. L., Chakravarty, E. E., Chambers, C., Clowse, M. E. B., Lockshin, M. D., Marder, W., Guyatt, G., Branch, D. W., Buyon, J., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41191 · Cited by 790
Self-citation
Metadata
- Authors
- Mariette, X., Förger, F., Abraham, B., Flynn, A. D., Moltó, A., Flipo, R.-M., van Tubergen, A., Shaughnessy, L., Simpson, J., Teil, M., Helmer, E., Wang, M., & Chakravarty, E. F.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 77
- Issue
- 2
- Pages
- 228-233
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2764022867
- Cited by
- 404
- References
- 24
- FWCI
- 31.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. https://app.cochat.ai/papers/10.1136/annrheumdis-2017-212196
- The paper
- Mariette, X., Förger, F., Abraham, B., Flynn, A. D., Moltó, A., Flipo, R.-M., van Tubergen, A., Shaughnessy, L., Simpson, J., Teil, M., Helmer, E., Wang, M., & Chakravarty, E. F. (2018). Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2017-212196
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.